A LARGE PRECISION MEDICINE CANCER INITIATIVE TO TEST THE EFFECTIVENESS OF TREATING ADULTS AND CHILDREN WITH NEW DRUG COMBINATIONS THAT TARGET SPECIFIC CANCEROUS TUMOR ALTERATIONS HAS LAUNCHED. KNOWN AS THE COMBINATION THERAPY PLATFORM TRIAL WITH MOLECULAR ANALYSIS FOR THERAPY CHOICE – OR ComboMATCH FOR SHORT -- THE INITIATIVE IS THE LARGEST OF ITS KIND TO TEST COMBINATIONS OF CANCER DRUGS GUIDED BY TUMOR BIOLOGY. DR. JEFFREY MOSCOW IN THE N-C-I’S DIVISION OF CANCER TREATMENT AND DIAGNOSIS SAYS THAT THE ENDEAVOR AIMS TO IDENTIFY PROMISING TREATMENTS THAT CAN ADVANCE TO LARGER, MORE DEFINITIVE CLINICAL TRIALS OUTSIDE OF COMBOMATCH.

Read More